SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of ...

Myriad Genetics is a leading molecular diagnostic testing and precision ... including statements relating to the transition of senior leadership at the Company, accelerating the Company's strategy to ...

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

Myriad Genetics develops and offers molecular tests ... including statements relating to the transition of senior leadership at the Company, accelerating the Company’s strategy to drive ...

Myriad Genetics is a leading molecular diagnostic ... including statements relating to the transition of senior leadership at the Company, accelerating the Company’s strategy to drive continued ...

Clara Peek, an expert on circadian rhythms, says small changes — like shifting sleep and meal times — can make a big ...

Clara Peek, an expert on circadian rhythms, says small changes — like shifting sleep and meal times — can make a big ...